The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Table 2

Clinical findings after SGLT2 inhibitor treatment in both models.

	Unmatched cohort ()			Matched cohort ()
	DPP4i ()	GLP1Ra ()	value	DPP4i ()	GLP1Ra ()	value
(a) Primary outcomes of this subanalysis
eGFR (mL/min/1.73 m^2)			0.44			0.29
CCr (mL/min)			<0.001			0.49
ΔeGFR (%)			0.08			0.10
Annual ΔeGFR (mL/min/1.73 m^2/year)			0.41			0.37
ACR	25.1 [10.4, 73.9]	34.9 [11.4, 125.4]	0.14	27.6 [9.7, 100.6]	31.2 [11.0, 125.6]	0.047
LNACR			0.08			0.45
ΔLNACR			0.66			0.90
(b) Other clinical findings after SGLT2i treatment
BW (kg)			0.05			0.89
BMI (kg/m^2)			0.08			0.93
SBP (mmHg)			0.93/0.14			0.66
DBP (mmHg)			0.33			0.62
HbA1c (mmol/mol (%))			0.18			0.02

Abbreviations are described in Table 1.